Compare PDS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | VIR |
|---|---|---|
| Founded | 1951 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 1.5B |
| IPO Year | 1998 | 2019 |
| Metric | PDS | VIR |
|---|---|---|
| Price | $96.30 | $9.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $114.50 | $19.63 |
| AVG Volume (30 Days) | 126.3K | ★ 4.2M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $6.09 | N/A |
| Revenue Next Year | $2.10 | $1,049.62 |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.20 | $4.16 |
| 52 Week High | $97.13 | $10.91 |
| Indicator | PDS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 72.77 | 55.65 |
| Support Level | $54.77 | $8.67 |
| Resistance Level | N/A | $10.29 |
| Average True Range (ATR) | 2.91 | 0.59 |
| MACD | 0.25 | -0.08 |
| Stochastic Oscillator | 92.55 | 40.12 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.